Literature DB >> 31163252

Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: A systematic review and meta-analysis.

Ali Purmohamad1, Elham Abasi2, Taher Azimi3, Sareh Hosseini4, Hossein Safari5, Mohammad Javad Nasiri6, Abbas Ali Imani Fooladi7.   

Abstract

Using the PRISMA guideline, 102 studies were included in this study. The highest and the lowest proportion of N. meningitidis serogroups in invasive meningococcal disease (IMD) was for NmB with 48.5% (95% CI: 45-52) and NmX with 0.7% (95% CI: 0.3-1.7). Among the WHO regional offices, serogroup NmW with 57.5% (95% CI: 35-77.5) in Eastern Mediterranean, and NmZ with 0.1% (95% CI: 0-0.9) in America had the highest and the lowest proportion of N. meningitidis serogroups in IMD. NmC with 9.7% (95% CI: 5.6-16.2) and NmB with 9.5% (95% CI: 0.2-3.8) had the highest proportion in 1-4 and <1 year age groups, respectively. Our analysis showed that NmB had the highest proportion of N. meningitidis serogroups in IMD worldwide. However, proportion of N. meningitidis serogroups in IMD varied noticeably across countries and age groups. Therefore, establishing appropriate control guidelines depending on the geographical regions and age groups is essential for prevention of IMD.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Meningococcal infections; Meta-analysis; Neisseria meningitidis; Serogroup

Year:  2019        PMID: 31163252     DOI: 10.1016/j.micpath.2019.103571

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  15 in total

1.  Carriage prevalence of Neisseria meningitidis in China, 2005-2022: a systematic review and meta-analysis.

Authors:  Mengmeng Yue; Juan Xu; Jianxing Yu; Zhujun Shao
Journal:  BMC Infect Dis       Date:  2022-07-07       Impact factor: 3.667

Review 2.  Rationale for the Development of a Pentavalent Meningococcal Vaccine: A US-Focused Review.

Authors:  Gary S Marshall; Jaime Fergie; Jessica Presa; Paula Peyrani
Journal:  Infect Dis Ther       Date:  2022-03-31

3.  Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines.

Authors:  Lidia Serra; Markus Knuf; Federico Martinón-Torres; Kevin Yi; Jamie Findlow
Journal:  Hum Vaccin Immunother       Date:  2021-02-19       Impact factor: 3.452

4.  A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years.

Authors:  Charissa Fay Corazon Borja-Tabora; Paula Peyrani; Chris Webber; Marie Van der Wielen; Brigitte Cheuvart; Nathalie De Schrevel; Veronique Bianco; Emmanuel Aris; Mark Cutler; Ping Li; John L Perez
Journal:  BMC Infect Dis       Date:  2020-06-18       Impact factor: 3.090

5.  Molecular characterization of Neisseria meningitidis isolates recovered from patients with invasive meningococcal disease in Colombia from 2013 to 2016.

Authors:  Jaime Moreno; Zonia Alarcon; Eliana Parra; Carolina Duarte; Olga Sanabria; Diego Prada; Jean Marc Gabastou
Journal:  PLoS One       Date:  2020-07-14       Impact factor: 3.240

6.  Clinical characteristics and molecular epidemiology of children with meningitis in Tehran, Iran: a prospective study.

Authors:  A Pormohammad; S Lashkarbolouki; T Azimi; P Gholizadeh; N Bostanghadiri; H Safari; S Armin; N Mohtavinejad; F Fallah
Journal:  New Microbes New Infect       Date:  2019-08-29

7.  Invasive Meningococcal Disease Remains a Health Threat in Vietnam People's Army.

Authors:  Chung Pham Van; The Trong Nguyen; Sy Tien Bui; Trong Van Nguyen; Huyen Thi Thanh Tran; Dong Trac Pham; Long Phi Trieu; Manh Dang Nguyen
Journal:  Infect Drug Resist       Date:  2021-12-08       Impact factor: 4.003

Review 8.  Invasive meningococcal disease in older adults in North America and Europe: is this the time for action? A review of the literature.

Authors:  Sandra Guedes; Isabelle Bertrand-Gerentes; Keith Evans; Florence Coste; Philipp Oster
Journal:  BMC Public Health       Date:  2022-02-23       Impact factor: 3.295

9.  Evolution of invasive meningococcal disease epidemiology in Europe, 2008 to 2017.

Authors:  Charles Nuttens; Jamie Findlow; Paul Balmer; David L Swerdlow; Myint Tin Tin Htar
Journal:  Euro Surveill       Date:  2022-01

Review 10.  Broad vaccine protection against Neisseria meningitidis using factor H binding protein.

Authors:  Jamie Findlow; Christopher D Bayliss; Peter T Beernink; Ray Borrow; Paul Liberator; Paul Balmer
Journal:  Vaccine       Date:  2020-08-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.